During the last session, Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares were 0.35 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stock’s price was $10.68, reflecting an intraday gain of 0.47% or $0.05. The 52-week high for the STOK share is $17.58, that puts it down -64.61 from that peak though still a striking 58.99% gain since the share price plummeted to a 52-week low of $4.38. The company’s market capitalization is $565.69M, and the average intraday trading volume over the past 10 days was 0.83 million shares, and the average trade volume was 756.07K shares over the past three months.
Stoke Therapeutics Inc (STOK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.20. STOK has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.54.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
Stoke Therapeutics Inc (STOK) registered a 0.47% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.47% in intraday trading to $10.68, hitting a weekly high. The stock’s 5-day price performance is -5.90%, and it has moved by 12.54% in 30 days. Based on these gigs, the overall price performance for the year is 159.22%. The short interest in Stoke Therapeutics Inc (NASDAQ:STOK) is 8.99 million shares and it means that shorts have 11.0 day(s) to cover.
The consensus price target of analysts on Wall Street is $26.5, which implies an increase of 59.7% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $35 respectively. As a result, STOK is trading at a discount of -227.72% off the target high and -68.54% off the low.
Stoke Therapeutics Inc (STOK) estimates and forecasts
In the rating firms’ projections, revenue will increase 98.32% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.2M as predicted by 9 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 2.83M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.8M and 4.22M respectively. In this case, analysts expect current quarter sales to grow by 49.89% and then drop by -32.99% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -44.06%. While earnings are projected to return 14.75% in 2025, the next five years will return -2.32% per annum.
STOK Dividends
Stoke Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
Stoke Therapeutics Inc insiders own 4.67% of total outstanding shares while institutional holders control 107.47%, with the float percentage being 112.73%. SKORPIOS TRUST is the largest shareholder of the company, while 179.0 institutions own stock in it. As of 2024-06-30, the company held over 10.84 million shares (or 23.4474% of all shares), a total value of $146.5 million in shares.
The next largest institutional holding, with 5.41 million shares, is of BLACKROCK INC.’s that is approximately 11.6963% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $73.08 million.
Also, the Mutual Funds coming in first place with the largest holdings of Stoke Therapeutics Inc (STOK) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.61 shares. This amounts to just over 3.04 percent of the company’s overall shares, with a $17.17 million market value. The same data shows that the other fund manager holds slightly less at 988.96, or about 1.87% of the stock, which is worth about $10.56 million.
